White-Koning M[au] - Search Results

Year	Number of Results
2004	1
2005	1
2006	1
2007	6
2008	5
2009	5
2010	1
2011	1
2012	1
2013	1
2014	2
2015	1
2016	3
2018	1
2019	2
2020	4
2021	7
2022	1
2024	1

1

Subjective quality of life in children with intellectual impairment--how can it be assessed?

White-Koning M, Arnaud C, Bourdet-Loubère S, Bazex H, Colver A, Grandjean H. White-Koning M, et al. Dev Med Child Neurol. 2005 Apr;47(4):281-5. doi: 10.1017/s0012162205000526. Dev Med Child Neurol. 2005. PMID: 15832552 Free article. Review. No abstract available.

2

[Compliance to treatment of adolescents with cancer].

White-Koning M, Bertozzi-Salamon AI, Vignes M, Arnaud C. White-Koning M, et al. Bull Cancer. 2007 Apr;94(4):349-56. Bull Cancer. 2007. PMID: 17449437 Free article. Review. French.

3

Preclinical Pharmacokinetics and Dosimetry of an ⁸⁹Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model.

Krache A, Fontan C, Pestourie C, Bardiès M, Bouvet Y, Payoux P, Chatelut E, White-Koning M, Salabert AS. Krache A, et al. Among authors: white koning m. Front Med (Lausanne). 2022 Jan 31;8:741855. doi: 10.3389/fmed.2021.741855. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35174180 Free PMC article.

4

Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients.

Allard M, Puszkiel A, Conti F, Chevillard L, Kamar N, Noé G, White-Koning M, Thomas-Schoemann A, Simon T, Vidal M, Calmus Y, Blanchet B. Allard M, et al. Among authors: white koning m. Clin Ther. 2019 May;41(5):882-896.e3. doi: 10.1016/j.clinthera.2019.03.006. Epub 2019 Apr 17. Clin Ther. 2019. PMID: 31003735 Clinical Trial.

5

Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data.

Le Louedec F, Gallais F, Thomas F, White-Koning M, Allal B, Protin C, Ysebaert L, Chatelut É, Puisset F. Le Louedec F, et al. Among authors: white koning m. Pharmaceuticals (Basel). 2021 Feb 18;14(2):162. doi: 10.3390/ph14020162. Pharmaceuticals (Basel). 2021. PMID: 33670575 Free PMC article.

6

Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.

Gallais F, Ysebaert L, Despas F, De Barros S, Obéric L, Allal B, Chatelut E, White-Koning M. Gallais F, et al. Among authors: white koning m. Clin Pharmacol Ther. 2021 Jul;110(1):220-228. doi: 10.1002/cpt.2189. Epub 2021 Mar 3. Clin Pharmacol Ther. 2021. PMID: 33539551

7

Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy.

Kurinczuk JJ, White-Koning M, Badawi N. Kurinczuk JJ, et al. Among authors: white koning m. Early Hum Dev. 2010 Jun;86(6):329-38. doi: 10.1016/j.earlhumdev.2010.05.010. Epub 2010 Jun 16. Early Hum Dev. 2010. PMID: 20554402

8

Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.

Gallais F, Ysebaert L, Despas F, De Barros S, Dupré L, Quillet-Mary A, Protin C, Thomas F, Obéric L, Allal B, Chatelut E, White-Koning M. Gallais F, et al. Among authors: white koning m. Clin Pharmacokinet. 2020 Sep;59(9):1171-1183. doi: 10.1007/s40262-020-00884-0. Clin Pharmacokinet. 2020. PMID: 32328976 Free article.

9

Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.

Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer JC, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet-Bach I, Filleron T, Roché H, Chatelut E, White-Koning M, Thomas F. Puszkiel A, et al. Among authors: white koning m. Clin Pharmacol Ther. 2019 Sep;106(3):585-595. doi: 10.1002/cpt.1404. Epub 2019 Apr 10. Clin Pharmacol Ther. 2019. PMID: 30786012 Clinical Trial.

10

Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.

Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL; CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. Mc Laughlin AM, et al. Among authors: white koning m. Clin Pharmacol Ther. 2024 Mar 18. doi: 10.1002/cpt.3238. Online ahead of print. Clin Pharmacol Ther. 2024. PMID: 38494911

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

38 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year